Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE * 3-Leiden.CETP mice

Journal of Nutritional Biochemistry

Volumn 24, Issue 8, 2013, Pages 1423-1430

  Berbée, Jimmy F P ^a,b   Wong, Man C ^a   Wang, Yanan ^a   van der Hoorn, José W A ^c   Khedoe, Padmini P S J ^a   van Klinken, Jan B ^a   Mol, Isabel M ^a   Hiemstra, Pieter S ^a   Tsikas, Dimitrios ^d   Romijn, Johannes A ^a,e   Havekes, Louis M ^a,c   Princen, Hans M G ^c   Rensen, Patrick C N ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

^c TNO   (Netherlands)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Atherosclerosis; Inflammation; Lipids; Oxidative stress; Resveratrol; Statin

Indexed keywords

ATORVASTATIN; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; COLLAGEN; LIPID; RESVERATROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IN VITRO STUDY; LIPID BLOOD LEVEL; MACROPHAGE; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE;

3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE; 8-ISO-PGF(2Α); APOE*3-LEIDEN TRANSGENIC; ATHEROSCLEROSIS; CETP; CHEMOKINE (C-X-C MOTIF) LIGAND-1; CHOLESTERYL ESTER TRANSFER PROTEIN COX1/-2, CYCLOOXYGENASE-1/-2; CXCL1; E3L; HMG-COA REDUCTASE; IG; IL; IMMUNOGLOBULIN; INFLAMMATION; INTERLEUKIN; ISOPROSTANE 15(S)-8-ISO-PROSTAGLANDIN F(2Α); LECTIN-LIKE OXIDIZED LOW-DENSITY LIPOPROTEIN RECEPTOR-1; LIPIDS; LIPOPOLYSACCHARIDE; LOX-1; LPS; MANGANESE SUPEROXIDE DISMUTASE; MCP-1; MNSOD; MONOCYTE CHEMOATTRACTANT PROTEIN-1; OXIDATIVE STRESS; OXIDIZED LDL; OXLDL; PARAOXONASE-1; PON1; REAL-TIME POLYMERASE CHAIN REACTION; RESVERATROL; RT-PCR; SE-SELECTIN; SMC; SMOOTH MUSCLE CELL; SOLUBLE E-SELECTIN; STATIN; TG; TRIGLYCERIDES; WESTERN-TYPE DIET; WTD;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL, DIETARY; CHOLESTEROL, LDL; DRUG SYNERGISM; FEMALE; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MICE; MICE, TRANSGENIC; OXIDATIVE STRESS; PYRROLES; STILBENES;

MUS;

EID: 84892432221     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2012.11.009     Document Type: Article

References (37)

1. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
2. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
3. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425:191-196.
4. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
5. Liu B.L., Zhang X., Zhang W., Zhen H.N. New enlightenment of French paradox: resveratrol's potential for cancer chemoprevention and anti-cancer therapy. Cancer Biol Ther 2007, 6:1833-1836.
6. Do G.M., Kwon E.Y., Kim H.J., Jeon S.M., Ha T.Y., Park T., et al. Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem Biophys Res Commun 2008, 374:55-59.
7. Miura D., Miura Y., Yagasaki K. Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats. Life Sci 2003, 73:1393-1400.
8. Penumathsa S.V., Thirunavukkarasu M., Koneru S., Juhasz B., Zhan L., Pant R., et al. Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. J Mol Cell Cardiol 2007, 42:508-516.
9. Csiszar A., Labinskyy N., Podlutsky A., Kaminski P.M., Wolin M.S., Zhang C., et al. Vasoprotective effects of resveratrol and SIRT1: attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations. Am J Physiol Heart Circ Physiol 2008, 294:H2721-H2735.
10. Kaneko H., Anzai T., Morisawa M., Kohno T., Nagai T., Anzai A., et al. Resveratrol prevents the development of abdominal aortic aneurysm through attenuation of inflammation, oxidative stress, and neovascularization. Atherosclerosis 2011, 217:350-357.
11. Martin A.R., Villegas I., Sanchez-Hidalgo M., de la Lastra C.A. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol 2006, 147:873-885.
12. Zou J.G., Huang Y.Z., Chen Q., Wei E.H., Hsieh T.C., Wu J.M. Resveratrol inhibits copper ion-induced and azo compound-initiated oxidative modification of human low density lipoprotein. Biochem Mol Biol Int 1999, 47:1089-1096.
13. Sebai H., Ben-Attia M., Sani M., Aouani E., Ghanem-Boughanmi N. Protective effect of resveratrol in endotoxemia-induced acute phase response in rats. Arch Toxicol 2009, 83:335-340.
14. Shen Z., Ajmo J.M., Rogers C.Q., Liang X., Le L., Murr M.M., et al. Role of SIRT1 in regulation of LPS- or two ethanol metabolites-induced TNF-alpha production in cultured macrophage cell lines. Am J Physiol Gastrointest Liver Physiol 2009, 296:G1047-G1053.
15. Fukao H., Ijiri Y., Miura M., Hashimoto M., Yamashita T., Fukunaga C., et al. Effect of trans-resveratrol on the thrombogenicity and atherogenicity in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Blood Coagul Fibrinolysis 2004, 15:441-446.
16. Matos R.S., Baroncini L.A., Precoma L.B., Winter G., Lambach P.H., Caron E.Y., et al. Resveratrol causes antiatherogenic effects in an animal model of atherosclerosis. Arq Bras Cardiol 2012, 2:136-142.
17. Delsing D.J., Jukema J.W., van de Wiel M.A., Emeis J.J., van der Laarse A., Havekes L.M., et al. Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE * 3-Leiden transgenic mice. J Cardiovasc Pharmacol 2003, 42:63-70.
18. van de Poll S.W., Romer T.J., Volger O.L., Delsing D.J., Bakker Schut T.C., Princen H.M., et al. Raman spectroscopic evaluation of the effects of diet and lipid-lowering therapy on atherosclerotic plaque development in mice. Arterioscler Thromb Vasc Biol 2001, 21:1630-1635.
19. de Haan W., de Vries-van der Weij J., van der Hoorn J.W., Gautier T., van der Hoogt C.C., Westerterp M., et al. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin. Circulation 2008, 117:2515-2522.
20. van der Hoorn J.W., de Haan W., Berbee J.F., Havekes L.M., Jukema J.W., Rensen P.C., et al. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler Thromb Vasc Biol 2008, 28:2016-2022.
21. Zadelaar S., Kleemann R., Verschuren L., de Vries-van der Weij J., van der Hoorn J., Princen H.M., et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 2007, 27:1706-1721.
22. Wong M.C., van Diepen J.A., Hu L., Guigas B., de Boer H.C., van Puijvelde G.H., et al. Hepatocyte-specific IKKbeta expression aggravates atherosclerosis development in APOE*3-Leiden mice. Atherosclerosis 2012, 220:362-368.
23. Leppanen P., Luoma J.S., Hofker M.H., Havekes L.M., Yla-Herttuala S. Characterization of atherosclerotic lesions in apo E3-leiden transgenic mice. Atherosclerosis 1998, 136:147-152.
24. Westerterp M., Berbee J.F., Pires N.M., van Mierlo G.J., Kleemann R., Romijn J.A., et al. Apolipoprotein C-I is crucially involved in lipopolysaccharide-induced atherosclerosis development in apolipoprotein E-knockout mice. Circulation 2007, 116:2173-2181.
25. Tsikas D., Schwedhelm E., Suchy M.T., Niemann J., Gutzki F.M., Erpenbeck V.J., et al. Divergence in urinary 8-iso-PGF(2alpha) (iPF(2alpha)-III, 15-F(2t)-IsoP) levels from gas chromatography-tandem mass spectrometry quantification after thin-layer chromatography and immunoaffinity column chromatography reveals heterogeneity of 8-iso-PGF(2alpha). Possible methodological, mechanistic and clinical implications. J Chromatogr B Analyt Technol Biomed Life Sci 2003, 794:237-255.
26. den Boer M.A., Westerterp M., de Vries-van der Weij J., Wang Y., Hu L., Espirito Santo S.M., et al. Ritonavir protects against the development of atherosclerosis in APOE*3-Leiden mice. Atherosclerosis 2010, 210:381-387.
27. Berbee J.F., Coomans C.P., Westerterp M., Romijn J.A., Havekes L.M., Rensen P.C. Apolipoprotein CI enhances the biological response to LPS via the CD14/TLR4 pathway by LPS-binding elements in both its N- and C-terminal helix. J Lipid Res 2010, 51:1943-1952.
28. Schwedhelm E., Benndorf R.A., Böger R.H., Tsikas D. Mass spectrometric analysis of F2-isoprostanes: markers and mediators in human disease. Curr Pharmacol Anal 2007, 3:39-51.
29. Steger A.S., Cochrane A.L., Moore F. Factors associated with cardiac mortality in developed countries with particular reference to the consumption of wine. Lancet 1979, 1:1017-1020.
30. Goldberg D.M., Yan J., Ng E., Diamandis E., Karumanchiri A., Soleas G., et al. A global survey of trans-resveratrol concentrations in commercial wines. Am J Enol Vitic 1995, 46:159-165.
31. Schwedhelm E., Bartling A., Lenzen H., Tsikas D., Maas R., Brummer J., et al. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 2004, 109:843-848.
32. Pal S., Ho N., Santos C., Dubois P., Mamo J., Croft K., et al. Red wine polyphenolics increase LDL receptor expression and activity and suppress the secretion of ApoB100 from human HepG2 cells. J Nutr 2003, 133:700-706.
33. Voloshyna I., Hai O., Littlefield M.J., Carsons S., Reiss A.B. Resveratrol mediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPARgamma and adenosine. Eur J Pharmacol 2013, 698:299-309.
34. Cho I.J., Ahn J.Y., Kim S., Choi M.S., Ha T.Y. Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters. Biochem Biophys Res Commun 2008, 367:190-194.
35. Berrougui H., Grenier G., Loued S., Drouin G., Khalil A. A new insight into resveratrol as an atheroprotective compound: inhibition of lipid peroxidation and enhancement of cholesterol efflux. Atherosclerosis 2009, 207:420-427.
36. Sevov M., Elfineh L., Cavelier L.B. Resveratrol regulates the expression of LXR-alpha in human macrophages. Biochem Biophys Res Commun 2006, 348:1047-1054.
37. Escher G., Krozowski Z., Croft K.D., Sviridov D. Expression of sterol 27-hydroxylase (CYP27A1) enhances cholesterol efflux. J Biol Chem 2003, 278:11015-11019.